ICoP India 2026 - Highlights
ICoP India 2026 brought together a global community of scientists, researchers, and innovators in the field of pharmacometrics.
The conference featured groundbreaking sessions, collaborative workshops, and vibrant community engagement across four dynamic days.
Participation Figures
Speakers & Topics
Dr. Rama Sivasubramanian
Director - R&D, Teva Pharmaceuticals, Maharashtra, India
Dr. Amit Roy
Vice President, Scientific & Strategic Consulting, PumasAI, USA
Impact of MIDD in Oncology
Dr. Mathangi Gopalakrishnan
Associate Professor, Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA
A Quantitative Framework to Assess Biomarkers as Surrogate Endpoints: Applications in Drug Development
Prof. Narendra Dixit
Professor, Department of Chemical Engineering and Bioengineering, IISc, Bengaluru, Karnataka, India
Modelling How Early Treatment Initiation Improves Post-Treatment Control of HIV Infection
Dr. Dhanashri Gudi
Vice President, Business Development & Strategy, Pumas-AI, Inc., USA
Reimagining Pharmacometrics: From Analysis to Decision-Making
Dr. Sivacharan Kollipara
Head - Biopharmaceutics, Global Clinical Management, Dr. Reddy’s Laboratories Ltd, Hyderabad, Telangana, India
Dr. Suraj Bhansali
R&D Data Science & Head of India Country Operations, Certara, Hyderabad, Telangana, India
Dr. Rajkumar Boddu
Team Lead Biopharmaceutics, Global Clinical management group, Dr. Reddy’s Laboratories Limited, Hyderabad, Telangana, India
Harnessing PBBM & PBPK modelling for Next-Generation Generic Drug Development
Ms. Maitri Sanghavi
Research Scientist, SIMCYP, Certara, Hyderabad, Telangana, India
Optimising & Enhancing Drug Development Using Simcyp PBPK Simulator
Dr. Sheila Annie Peters
Executive Director, Boehringer Ingelheim, Germany.
Hypothesis Generation With PBPK to Identify Mechanisms Limiting Exposure of Orally Administered Drugs
Dr. Samarth Thakore
Principal Scientist II - PK Sciences, NIBR, Novartis, Hyderabad, Telangana, India
Physiologically-Based Pharmacokinetic Modelling: An Integral Component of Model-Informed Drug Development
Dr. Anant Ketkar
Principal Scientist and Scientific Lead - India, Simulations Plus, Inc
Physiologically Based IVIVC for Complex Formulations: Focus on Long-Acting Injectables
Dr. Bhairav Paleja
Principal Scientist, Vantage Research, Chennai, Tamil Nadu, India
Dr. Balaji Agoram
Senior Vice President, Arcus Biosciences, Brisbane, CA, USA
Prof. Krishna R. Devarakonda
Visiting and Adjunct Professor, Thomas J.Long School of Pharmacy, University of the Pacific Richmond, Tx, USA
Dr. Ramalingam Sankaran Commemoration Lecture: From Sheiner to Systems: Evolving Personalized Dosing in the Era of Precision Medicine
Dr. Kannan Thiagarajan
Principal Scientist, Vantage Research, Chennai, India
Does Progressive Disease Justify Discontinuation: A Simulation Analysis
Dr. Khamir Mehta
Senior Director, Clinical Pharmacology modelling and Simulation Department San Francisco, CA, USA
The Role of Mechanistic Models to Complement Pharmacometrics in Model-Informed Drug Development
Dr. Karthick Vishwanathan
Executive Director - Head CPQP Oncology, AstraZeneca Waltham Site Head Waltham, MA, USA
Novel modelling Approaches Towards Dose Optimization of TCEs
Recap
The International Conference on Pharmacometrics India (ICOP 2026) was a tremendous success, bringing together global thought leaders in drug development, clinical pharmacology, and healthcare data analytics. The event, hosted by SOPHAS in collaboration with the International Society of Pharmacometrics, Manipal Academy of Higher Education and Manipal College of Pharmaceutical Sciences (MCOPS), Manipal, has further solidified our commitment to driving innovation in quantitative sciences.
This year’s sessions focused on cutting-edge topics such as:
- Quantitative Methods for Drug Development Decision
- Quantitative Science in Generic and New Drug Development (Small Molecules)
- Quantitative Sciences in Biologics, Biosimilars and New Modalities (Large Molecules)
SOPHAS continues to be at the forefront of advancing pharmacometrics, clinical pharmacology, and healthcare data analytics, with a mission to empower professionals globally. As we embrace emerging fields like machine learning applications, we remain committed to providing top-notch education and fostering collaboration across academia, industry, and regulatory bodies.
The energy, learning, and networking at ICOP 2026 have only reinforced the importance of this platform in the advancement of model-informed drug development. The journey doesn’t end here – stay tuned as we continue to develop impactful training programs, research initiatives, and global partnerships.
Gala Night
The Gala Night was a vibrant conclusion to ICOP 2026, featuring live musical performances by Tridentity, a three-piece ensemble showcasing violin, keyboard, and percussion.
Important Dates
October 01, 2024
January 05, 2025
December 25, 2024
January 15, 2025
January 30 & 31, 2025
February 01 & 02, 2025
Sponsors
Diamond Partner
Gold Partners
Silver Partners
Student Travel Support
Community Support
Join us for ICoP India 2027
Registration Fee Details
Indian Registrations ( INR )
|
|
Early Bird (Till Dec 24 2024)
|
Late Registration (Dec 25 to Jan 15)
|
|---|---|---|
|
Students/Trainees
|
6000
|
7000
|
|
Academia
|
7000
|
8000
|
|
Industry
|
12000
|
14000
|
International Registrations ( USD )
|
|
Early Bird (Till Dec 24 2024)
|
Late Registration (Dec 25 to Jan 15)
|
|---|---|---|
|
Students/Trainees
|
125
|
150
|
|
Academia
|
150
|
200
|
|
Industry
|
250
|
300
|
Pre-conference workshop during ICOP-India 2025
Accommodation Details
ICOP 2025 Abstract Submission Guidelines
Original research work from following areas will be accepted
- Quantitative approaches in drug development
- PKPD models
- Clinical Pharmacometrics
- Methodological studies
- PBPK modeling for drug drug interactions
- PBBM absorption modeling
- Bioequivalence risk assessments using modeling approaches
- Biostudy waivers using novel modeling approaches
Author:
Please provide information on all the authors with their affiliations and email id for corresponding author. The presenting author should be underlined. The same author list will appear in the abstract book.
Language:
All abstracts must be in English
Abstract Body:
The work published in previous national or international meetings or journals will not be accepted. The abstract should contain the statement on hypothesis or objective, the methods used, results and conclusion. The font of text should be Times New Roman with 12 font size. Abstract text should be typed single-spaced and with maximum 300 words. Type the text as one paragraph. All references included in the abstract should be numbered and accompanied by the full citation, including authors names, title, journal name, volume, number, inclusive paging, and year of publication